Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Tait D. Shanafelt; Sameer A. Parikh; Peter A. Noseworthy; Valentin Goede; Kari G. Chaffee; Jasmin Bahlo; Timothy G. Call; Susan M. Schwager; Wei Ding; Barbara Eichhorst; Kirsten Fischer; Jose F. Leis; Asher Alban Chanan-Khan; Michael Hallek; Susan L. Slager; Neil E. Kay

doi:10.1080/10428194.2016.1257795

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Tait D. Shanafelt, Sameer A. Parikh, Peter A. Noseworthy, Valentin Goede, Kari G. Chaffee, Jasmin Bahlo, Timothy G. Call, Susan M. Schwager, Wei Ding, Barbara Eichhorst, Kirsten Fischer, Jose F. Leis, Asher Alban Chanan-Khan, Michael Hallek, Susan L. Slager, Neil E. Kay

Research output: Contribution to journal › Article › peer-review

52 Scopus citations

Abstract

Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p <.0001), male sex (p =.01), valvular heart disease (p =.001), and hypertension (p =.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

Original language	English (US)
Pages (from-to)	1630-1639
Number of pages	10
Journal	Leukemia and Lymphoma
Volume	58
Issue number	7
DOIs	https://doi.org/10.1080/10428194.2016.1257795
State	Published - Jul 3 2017

Keywords

Chronic lymphocytic leukemia
atrial fibrillation
ibrutinib
risk factors

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2016.1257795

Cite this

Shanafelt, T. D., Parikh, S. A., Noseworthy, P. A., Goede, V., Chaffee, K. G., Bahlo, J., Call, T. G., Schwager, S. M., Ding, W., Eichhorst, B., Fischer, K., Leis, J. F., Chanan-Khan, A. A., Hallek, M., Slager, S. L., & Kay, N. E. (2017). Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). Leukemia and Lymphoma, 58(7), 1630-1639. https://doi.org/10.1080/10428194.2016.1257795

Shanafelt, TD, Parikh, SA , Noseworthy, PA, Goede, V, Chaffee, KG, Bahlo, J, Call, TG, Schwager, SM, Ding, W, Eichhorst, B, Fischer, K, Leis, JF, Chanan-Khan, AA, Hallek, M, Slager, SL & Kay, NE 2017, 'Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)', Leukemia and Lymphoma, vol. 58, no. 7, pp. 1630-1639. https://doi.org/10.1080/10428194.2016.1257795

@article{3e1da7d901f3425785659f0087ecba5e,

title = "Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)",

abstract = "Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p <.0001), male sex (p =.01), valvular heart disease (p =.001), and hypertension (p =.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.",

keywords = "Chronic lymphocytic leukemia, atrial fibrillation, ibrutinib, risk factors",

author = "Shanafelt, {Tait D.} and Parikh, {Sameer A.} and Noseworthy, {Peter A.} and Valentin Goede and Chaffee, {Kari G.} and Jasmin Bahlo and Call, {Timothy G.} and Schwager, {Susan M.} and Wei Ding and Barbara Eichhorst and Kirsten Fischer and Leis, {Jose F.} and Chanan-Khan, {Asher Alban} and Michael Hallek and Slager, {Susan L.} and Kay, {Neil E.}",

note = "Publisher Copyright: {\textcopyright} 2016 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = jul,

day = "3",

doi = "10.1080/10428194.2016.1257795",

language = "English (US)",

volume = "58",

pages = "1630--1639",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "7",

}

TY - JOUR

T1 - Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

AU - Shanafelt, Tait D.

AU - Parikh, Sameer A.

AU - Noseworthy, Peter A.

AU - Goede, Valentin

AU - Chaffee, Kari G.

AU - Bahlo, Jasmin

AU - Call, Timothy G.

AU - Schwager, Susan M.

AU - Ding, Wei

AU - Eichhorst, Barbara

AU - Fischer, Kirsten

AU - Leis, Jose F.

AU - Chanan-Khan, Asher Alban

AU - Hallek, Michael

AU - Slager, Susan L.

AU - Kay, Neil E.

PY - 2017/7/3

Y1 - 2017/7/3

N2 - Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p <.0001), male sex (p =.01), valvular heart disease (p =.001), and hypertension (p =.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

AB - Although preliminary data suggests that ibrutinib may increase risk of atrial fibrillation (AF), the incidence of AF in a general cohort of chronic lymphocytic leukemia (CLL) patients is unknown. We evaluated the prevalence of AF at CLL diagnosis and incidence of AF during follow-up in 2444 patients with newly diagnosed CLL. A prior history of AF was present at CLL diagnosis in 148 (6.1%). Among the 2292 patients without history of AF, 139 (6.1%) developed incident AF during follow-up (incidence approximately 1%/year). Older age (p <.0001), male sex (p =.01), valvular heart disease (p =.001), and hypertension (p =.04) were associated with risk of incident AF on multivariate analysis. A predictive model for developing incident AF constructed from these factors stratified patients into 4 groups with 10-year rates of incident AF ranging from 4% to 33% (p <.0001). This information provides context for interpreting rates of AF in CLL patients treated with novel therapies.

KW - Chronic lymphocytic leukemia

KW - atrial fibrillation

KW - ibrutinib

KW - risk factors

UR - http://www.scopus.com/inward/record.url?scp=84997079264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997079264&partnerID=8YFLogxK

U2 - 10.1080/10428194.2016.1257795

DO - 10.1080/10428194.2016.1257795

M3 - Article

C2 - 27885886

AN - SCOPUS:84997079264

SN - 1042-8194

VL - 58

SP - 1630

EP - 1639

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 7

ER -

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this